Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia

James M. McKiernan, Franklin C. Lowe

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia. We analyzed seven prospectively designed placebo-controlled trials involving 3,080 patients, 1,689 of whom received the study drug in doses ranging from 1 mg to 20 mg daily for a total of 1,282 patient-years of exposure. The most common side effects seen in treated patients were dizziness (10.7%), asthenia (7.5%), and peripheral edema (4.0%). These side effects were generally reported as mild and improved after cessation of therapy. The incidence of withdrawal from the study due to side effects was 14.5% in the treatment arm versus 11.4% in the placebo control arm. Also noted was a statistically significant decreased risk of urinary tract infection and myocardial infarction in the terazosin- treated group. This updated report confirms that terazosin can be administered safely to a population of men with symptomatic benign prostatic hyperplasia with minimal clinically significant side effects.

Original languageEnglish (US)
Pages (from-to)509-523
Number of pages15
JournalSouthern Medical Journal
Volume90
Issue number5
StatePublished - May 1997
Externally publishedYes

Fingerprint

Terazosin
Prostatic Hyperplasia
Placebos
Asthenia
Dizziness
Therapeutics
Urinary Tract Infections
Edema
Cohort Studies
Myocardial Infarction
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. / McKiernan, James M.; Lowe, Franklin C.

In: Southern Medical Journal, Vol. 90, No. 5, 05.1997, p. 509-523.

Research output: Contribution to journalArticle

@article{a07b0b54061b4fc995bc98c7e88c16d2,
title = "Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia",
abstract = "In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia. We analyzed seven prospectively designed placebo-controlled trials involving 3,080 patients, 1,689 of whom received the study drug in doses ranging from 1 mg to 20 mg daily for a total of 1,282 patient-years of exposure. The most common side effects seen in treated patients were dizziness (10.7{\%}), asthenia (7.5{\%}), and peripheral edema (4.0{\%}). These side effects were generally reported as mild and improved after cessation of therapy. The incidence of withdrawal from the study due to side effects was 14.5{\%} in the treatment arm versus 11.4{\%} in the placebo control arm. Also noted was a statistically significant decreased risk of urinary tract infection and myocardial infarction in the terazosin- treated group. This updated report confirms that terazosin can be administered safely to a population of men with symptomatic benign prostatic hyperplasia with minimal clinically significant side effects.",
author = "McKiernan, {James M.} and Lowe, {Franklin C.}",
year = "1997",
month = "5",
language = "English (US)",
volume = "90",
pages = "509--523",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia

AU - McKiernan, James M.

AU - Lowe, Franklin C.

PY - 1997/5

Y1 - 1997/5

N2 - In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia. We analyzed seven prospectively designed placebo-controlled trials involving 3,080 patients, 1,689 of whom received the study drug in doses ranging from 1 mg to 20 mg daily for a total of 1,282 patient-years of exposure. The most common side effects seen in treated patients were dizziness (10.7%), asthenia (7.5%), and peripheral edema (4.0%). These side effects were generally reported as mild and improved after cessation of therapy. The incidence of withdrawal from the study due to side effects was 14.5% in the treatment arm versus 11.4% in the placebo control arm. Also noted was a statistically significant decreased risk of urinary tract infection and myocardial infarction in the terazosin- treated group. This updated report confirms that terazosin can be administered safely to a population of men with symptomatic benign prostatic hyperplasia with minimal clinically significant side effects.

AB - In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia. We analyzed seven prospectively designed placebo-controlled trials involving 3,080 patients, 1,689 of whom received the study drug in doses ranging from 1 mg to 20 mg daily for a total of 1,282 patient-years of exposure. The most common side effects seen in treated patients were dizziness (10.7%), asthenia (7.5%), and peripheral edema (4.0%). These side effects were generally reported as mild and improved after cessation of therapy. The incidence of withdrawal from the study due to side effects was 14.5% in the treatment arm versus 11.4% in the placebo control arm. Also noted was a statistically significant decreased risk of urinary tract infection and myocardial infarction in the terazosin- treated group. This updated report confirms that terazosin can be administered safely to a population of men with symptomatic benign prostatic hyperplasia with minimal clinically significant side effects.

UR - http://www.scopus.com/inward/record.url?scp=0030929074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030929074&partnerID=8YFLogxK

M3 - Article

VL - 90

SP - 509

EP - 523

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 5

ER -